YvetteMaechellePoindexterMD
Obstetrics & Gynecology • Alvin, TXChief Medical Officer at Community Health Network
Dr. Poindexter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1111 W Adoue St
Alvin, TX 77511Phone+1 281-824-1480Fax+1 877-489-2319- Is this information wrong?
Summary
- Yvette M. Poindexter, M.D., F.A.C.O.G.
Yvette M. Poindexter, M.D. is a board certified Obstetrician-Gynecologist who has been is the Chief Medical Officer for Community Health Network. She graduated from University of Texas Medical Branch in 1993 and Baylor College of Medicine in 1997. Since her arrival she has helped to implement two prenatal programs in the Brazoria County service area including Alvin and Freeport. Dr.Poindexter’s greatest strength is her commitment to the mission of providing health care to all people without prejudice, in a caring manner, regardless of their ability to pay. This in particular will allow CHN patients to be successful in their medical management and preventative maintenance.
Education & Training
Baylor College of MedicineResidency, Obstetrics and Gynecology, 1993 - 1997- Baylor College of MedicineChief Residency, Obstetrics and Gynecology, 1992 - 1993
University of Texas Medical Branch School of MedicineClass of 1993
Spelman CollegeBS, Biology, Cum Laude, 1985 - 1989
Certifications & Licensure
TX State Medical License 1996 - 2024- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- Maintenance of American Board of Obstetrics and Gynecology Obstetrics and Gynecology
Awards, Honors, & Recognition
- Person to Person Talk Show KCOH Radio Talk Show
- Movers and Shakers of Houston IX Media
- Who's Who Among Executives and Professional Women Biltmore, 2007, 2015
- Join now to see all
Publications & Presentations
PubMed
- 5 citationsPrevious cesarean section. A contraindication to vaginal hysterectomyYvette M. Poindexter, Haleh Sangi-Haghpeykar, Alfred N. Poindexter, Nikolaos Thomakos, Ronald L. Young, Paul Fine, Harold J. Miller> ;The Journal of Reproductive Medicine. 2001 Sep 1
Committees
- CMO, Culture of Excellence 2018 - Present
- Chairperson, Risk Management 2017 - Present
- CMO, Executive Committee 2010 - Present
- CMO, Peer Review 2010 - Present
- CMO, Credentialing and Privileging 2010 - Present
- CMO, Continuous Quality Improvement 2010 - Present
Research History
- A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study-TherapeuticsIntravaginal ****** (*****) Against Vulvovaginal Atrophy Associated with Menopause2014 - Present
- A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study-EndoceuticsMulti-Center Study to Evaluate The Safety and Efficacy of **** in Combination with ***** in Postmenopausal Women with an Intact Uterus: **** to Reduce the Frequency and Severity of Vasomotor Symptoms and Progesterone to Manage the Incidence of endometrial hyperplasia2014 - Present
- A Phase 2, Multi-Center, Three-Arm, Parallel Design, Randomized, Double-Blind Study-Repros TherapeuticsEvaluate the Safety and Efficacy of 6 and 12 mg (*********) Administered Orally in the Treatment of Premenopausal Women with Confirmed Symptomatic Endometriosis2013 - Present
- A Randomized, Double-Blind, Placebo-Controlled Study-ABBVIEEvaluate the Safety and Efficacy of ****** in Subjects with Moderate to Severe Endometriosis-Associated Pain2013 - Present
- A Randomized, Placebo-Controlled, Parallel-Group-Watson LaboratoriesMulti-center Study to Evaluate the Efficacy and Safety of ******* for the Intermittent Treatment of Abnormal Uterine Bleeding Associated with Leiomyomas2013 - Present
- A Randomized, Double Blind, Placebo Controlled, Multicenter Study-Serenity PharmaceuticalsInvestigate the Efficacy and Safety of SER***Nasal****Formulation in Patients with Nocturia.2013 - 2015
- A Double-Blind Crossover Study-Repros TherapeuticsHealthy Volunteers to Compare Two Formulations of ******** for Oral Administration2014 - 2014
- An Observational Study -Repros TherapeuticsWomen with Menorrhagia to Develop a Pictogram for the Assessment of Menstrual Blood Loss.2014 - 2014
- A Phase III Randomized, Double-Blind, Placebo-Controlled-Merck Sharp & Dohme CorpEvaluate the Effects of *** on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with an Oral Bisphosphonate2013 - 2014
- A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study- Repros TherapeuticsMen with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with 12.5 mg or 25 mg ********or ******%.2013 - 2014
Professional Memberships
- Member
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
